We are developing a radiopharmaceutical that targets TAM (tumor associate macrophage) without any targeting ligand. Thought that was impossible, think again. Because our radiopharmaceutical is an HDT (hydroxyl dendrimer therapeutic) it comes with minimum toxicity to patients.

💪🙌

The results only get better! Ashvattha is showing improved interim results for our drug Migaldendranib for DME (Diabetic Macular Edema) and Wet AMD (Age-related Macular Degeneration). If this continues, not only could we achieve our goal of one single intravitreal injection every

1/ Natural Capital Natural Capital is thrilled to co-lead Varda Space Industries $187 MM Series C with Shrug Capital , alongside Founders Fund , Peter Thiel, Lux Capital , Khosla Ventures , Raymond Tonsing & others. Also excited to announce that I have joined the board. Jay Z Moshe Lifschitz

Psyched to join delian, Will Bruey and Varda Space Industries on this quest! Thanks to Ravi Tanuku, Moshe Lifschitz for championing this. 💪